BiotechnologyEvents.Com offers a unique and powerful tool that allows the user to mine the biotechnology sector for the all important events that effect the future success of the biotech companies covered.
Our database, which is updated daily, categorizes each event by specific “event type” (Regulatory PDUFA or MAA date, FDA Advisory Committee Meeting, phase II or III trial results, submission of a NDA, BLA, MAA etc., initiation or enrollment completion of a clinical trial and many other company specific issues such as licensure and partnering of compounds, patent litigation milestones and mergers and acquisitions activity). Each event type contains a documented date or time frame. The user can search the database by various parameters including: Event type, Company, Compound and Indication.
Additional information surrounding each compound includes: mechanism of action, molecule type, target, class, and phase of development.
The Biotechnologyevents.com data base also includes a "general calendar" that tracks various industry sensitive events including: scientific/medical conferences, investor/analyst conferences, earnings conference calls and FDA meetings.
Our search tool allows the user to search the database via four distinct parameters: Event type, Company, Compound and Indication. The user can also combine parameters to expand the search capability, a feature that allows the user to find correlated events of various types (see below).
Filter on Event Type
Searching by "event type" is an excellent way to get started. There are 4 main categories within the event filter (Corporate, Data, Legal and Regulatory)
Regulatory events such as the approval of a drug candidate or an opinion issued by a regulatory agency's review unit (U.S. approval via the FDA (Regulatory FDA: PDUFA DATE), E.U. approval via the EMA (Regulatory EMA: MAA approval), (Regulatory FDA: Advisory Committee Meeting) and (Regulatory EMA: CHMP opinion) often present as key inflection points in a company's history.
Smaller companies with one late stage drug candidate can often be impacted by less definitive regulatory events such as the submission of a New Drug Application (NDA), Biological Licensing Application (BLA) or Marketing Authorization Application (MAA) or some other company specific regulatory event.
Data releases are the second major "event type" category. Phase III trial results are by far the most important data releases, however for smaller companies and for certain disease areas phase II and proof of concept data results can also be very important.
Corporate events such as the attainment of a licensing or partnership agreement or a merger and acquisition can be strong drivers of a company's value. While it is difficult to place a specific date on such an event, time frames are often commented on by management.
Legal events such as patent litigation and patent grants are also often closely watched, especially for major drugs relative to a companies overall portfolio and for key indications.
Filter on Company
Once you have settled on a specific event you may want to conduct a search of the company involved. The search results will include all the relevant events for that company listed in chronological order. Please note, events such as earnings releases, conference calls and scientific conference participation can be found on the general event calendar.
Having a knowledge of all the possible inflection points surrounding your event of interest can be useful when planning an action or for purposes of monitoring the overall situation.
Filter on Indication
Correlated events arise when two or more compounds are related by indication or mechanism. There are many "event types" that can be of impact, however the most common is clinical trial data, followed next by regulatory approval and agency opinion.
The user can search by indication and add any important events within that disease space to the company specific events to achieve an even greater level of detail and comfort for the position.